Assuring vaccine safety: A celebration of 10 years of progress with the IMPACT project

Paediatrics and Child Health

Volumn 7, Issue 9, 2002, Pages 645-648

  Scheifele, David W ^a   Halperin, Scott A ^b   Gold, Ronald ^b   Samson, Heather ^b   King, Arlene ^b  

^a BC CHILDREN S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; TETANUS TOXOID;

ARTICLE; BACTERIAL INFECTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE CONVULSION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNIZATION; INCIDENCE; MEDICAL INFORMATION; MUSCLE HYPOTONIA; PUBLICATION; RISK FACTOR; THROMBOCYTOPENIA; VACCINATION;

EID: 0036871105     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/7.9.645     Document Type: Article

References (14)

1. McDonald JC, Moore DL, Quennec P. Clinical and epidemiologic features of mumps meningoencephalitis and possible vaccine-related disease. Pediatr Infect Dis J 1989;8:751-5.
2. Synopsis of a workshop on post-marketing surveillance of vaccine-associated adverse events. Can Dis Weekly Rep 1991;7:97-8.
3. Morris R, Halperin SA, Déry P, et al. IMPACT monitoring network: A better mousetrap. Can J Infect Dis 1993;4:194-5.
4. Gold R, Déry P, Halperin S, et al. Pertussis in children hospitalized at five Canadian pediatric tertiary care centers. Can Commun Dis Rep 1994;20:31-4.
5. Immunization Monitoring Program, Active (IMPACT). Recent trends in pediatric Haemophilus influenzae type b infections in Canada. CMAJ 1996;154:1041-7.
6. Scheifele DW, Gold R, Marchessault V, Duclos P. Failures after immunization with Haemophilus influenzae type b vaccines, 1991-1995. Can Commun Dis Rep 1996;22:17-23.
7. Scheifele D, Halperin S, Vaudry W, et al. Historic low Haemophilus influenzae type b case tally - Canada, 2000. Can Commun Dis Rep 2001;27:149-50.
8. Scheifele DW, Bell A, Jadavji T, et al. Population-based surveillance of Haemophilus influenzae type b invasive infections in children in British Columbia, Alberta and Ontario: 1995-1997. Can J Infect Dis 2000;11:135-40.
9. Scheifele DW, Law B, Jadavji T. Disseminated Bacille Calmette-Guérin infection: Three recent Canadian cases. IMPACT. Immunization Monitoring Program, Active. Can Commun Dis Rep 1998;24:69-72.
10. Scheifele DW, Halperin SA, Pless R, et al. Marked reduction in febrile seizures and hypotonic-hyporesponsive episodes with acellular pertussis-based vaccines: Results of Canada-wide surveillance, 1995-1998. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania, November 18-21, 1999. (Abst)
11. Law B, MacDonald N, Halperin S, et al. The Immunization Monitoring Program, Active (IMPACT) prospective 5-year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J 2000;19:1053-9.
12. Halperin SA, Wang EL, Law B, et al. Epidemiologic features of pertussis in hospitalized patients in Canada, 1991-1997: Report of the Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis 1999;28:1238-43.
13. Scheifele DW, Halperin SA, Pelletier L, et al. Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies. Clin Infect Dis 2000;31:58-64.
14. Bjornson G, Scheifele D, Halperin S, et al. Population-based incidence rates of invasive pneumococcal infection in children in seven centers across Canada, 1994-1998. 4th Annual Vaccine Research Conference, Arlington, Virginia, April 23-25, 2001. (Abst)